Meike Hutt

Paul Ehrlich Str. 15
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

Journal: mAbs

Published: September 01, 2026

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: June 19, 2026

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: April 17, 2026

An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions.

An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions.

Journal: Scientific reports

Published: January 20, 2023

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

Journal: Science translational medicine

Published: August 31, 2022

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.

Journal: Cell death and differentiation

Published: March 05, 2019

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.

Journal: NPJ systems biology and applications

Published: June 20, 2018

IgG-single-chain TRAIL fusion proteins for tumour therapy.

IgG-single-chain TRAIL fusion proteins for tumour therapy.

Journal: Scientific reports

Published: February 02, 2018

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Journal: Oncotarget

Published: December 14, 2017

Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Journal: Molecular cancer therapeutics

Published: June 14, 2017

Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Journal: mAbs

Published: April 20, 2017

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.

Journal: Frontiers in immunology

Published: February 24, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026